MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    Concerns in patients with Parkinson’s disease in China: A content analysis of data from social listening

    Y. Qian, X. Yang, S. Xu, X. He, Y. Zhang, C. Mo, Q. Xiao (Shanghai, China)

    Objective: To understand Parkinson’s disease (PD) patients’ unmet needs and optimize the communication strategy with them, we used social media listening (SML) to focus on…
  • MDS Virtual Congress 2020

    Utility of multigene panel testing for diagnosing parkinsonism and dystonia in a large cohort of >500 patients

    H. Zghal Elloumi, M. Stosser, A. Lindy (Gaithersburg, MD, USA)

    Objective: Evaluate the utility of multigene Next-Generation Sequencing (NGS) for molecular diagnosis of parkinsonism and dystonia. Background: Parkinson's disease (PD) and dystonia are common neurodegenerative…
  • MDS Virtual Congress 2020

    Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease

    M. Geva, A. McGarry, Y. Cohen, T. Johnston, M. de Somer, K. Kieburtz, M. Hayden, J. Brotchie, C. Olanow (Herzliya, Israel)

    Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…
  • MDS Virtual Congress 2020

    Levodopa Dose Equivalency for Opicapone and Safinamide

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)

    Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…
  • MDS Virtual Congress 2020

    PNPLA6-related Disorder With Expanded Phenotype Including Parkinsonism, Dystonia, And Abnormal Dopamine Transporter Imaging

    J. Witt, M. Davis (Seattle, WA, USA)

    Objective: To present a case of PNPLA6-related disorder with an expanded phenotype. Background: PNPLA6-related are autosomal recessive disorders with heterogeneous clusters of cerebellar ataxia, upper…
  • MDS Virtual Congress 2020

    Alpha-synuclein DNA methylation in CD45+ blood cells in Parkinson’s disease

    A. Lavrinova, N. Melnikova, A. Dmitriev, I. Miliukhina, E. Litusova, P. Gagarina, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

    Objective: We examined the methylation status of the DNA SNCA-intron1 at CD45+ blood cells in patients with sporadic Parkinson's disease (PD). Background: PD is a…
  • MDS Virtual Congress 2020

    Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study

    S. Isaacson, W. Poewe, T. Simuni, O. Rosenfeld, R. Case, T. Yardeni, W. Olanow (Boca Raton, FL, USA)

    Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…
  • MDS Virtual Congress 2020

    Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

    Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…
  • MDS Virtual Congress 2020

    Motor- and Non-motor Symptoms in Patients Treated with 24-hour Daily Levodopa-Carbidopa Intestinal Gel Infusion: Analysis of the COSMOS Observational Study

    N. Kovács, J. Szász, L. Vela-Desojo, P. Svenningsson, S. Femia, J. Carlos Parra, A. Fasano (Pécs, Hungary)

    Objective: Describe and compare demographic and clinical characteristics, motor, and non-motor symptoms for patients with advanced Parkinson’s disease (APD) by daily duration (<24 hours or…
  • MDS Virtual Congress 2020

    Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias

    C.T Gan, M. Wang, QQ. Si, Y.S Yuan, Y. Zhi, L.N Wang, K.W Ma (Nanjing, China)

    Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley